Multiple squamous cell carcinomas following introduction of nilotinib-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Multiple squamous cell carcinomas following introduction of nilotinib

Published:2014-08-22 Issue:7 Volume:39 Page:791-794
ISSN:0307-6938
Container-title:Clinical and Experimental Dermatology
language:en
Short-container-title:Clin Exp Dermatol

Author:

Peters P.¹²,Rabbolini D.³,Sinnya S.¹⁴,Khosrotehrani K.¹⁴,Wagner G.¹

Affiliation:

1. Queensland Institute of Dermatology; Brisbane QLD Australia

2. School of Medicine; University of Queensland; Brisbane QLD Australia

3. University of Queensland Diamantina Institute; Translational Research Institute; Brisbane QLD Australia

4. Haematology Department; The Canberra Hospital; Canberra ACT Australia

Publisher

Wiley

Subject

Dermatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ced.12388/fullpdf

Reference23 articles.

1. Chronic myelogenous leukemia: an update on the biological findings and therapeutic approaches;Ferrajoli;Crit Rev Oncol Hematol,1996

2. Targeted treatment of chronic myeloid leukemia: role of imatinib;Tamascar;Onco Targets Ther,2009

3. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia;Deremer;Clin Ther,2008

4. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance;Kantarjian;Blood,2007

5. Bullous sweet syndrome in a patient with t(9;22) (q34;q11)-positive chronic myeloid leukemia treated with the tyrosine kinase inhibitor nilotinib: interphase cytogenetic detection of BCR-ABL-positive lesional cells;Kaune;Arch Dermatol,2008

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular and immune targets in cutaneous squamous cell carcinoma;Molecular Carcinogenesis;2022-08-24

2. Incidence of Second Malignancies of Chronic Myeloid Leukemia During Treatment With Tyrosine Kinase Inhibitors;Clinical Lymphoma Myeloma and Leukemia;2016-10

3. Adverse Drug Reactions of the Lower Extremities;Clinics in Podiatric Medicine and Surgery;2016-07

4. Nilotinib;Reactions Weekly;2015-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3